Direct molecular targets of resveratrol: identifying key interactions to unlock complex mechanisms

Annals of the New York Academy of Sciences

Volumn 1348, Issue 1, 2015, Pages 124-133

  Britton, Robert G ^a   Kovoor, Christina ^a   Brown, Karen ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

cancer; cardiovascular; inflammation; mechanism; protein targets; resveratrol

Indexed keywords

RESVERATROL;

ARTICLE; CELL CYCLE REGULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TARGETING; HUMAN; INFLAMMATION; NONHUMAN; PROTEIN PROCESSING; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

EID: 84932144505     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.12796     Document Type: Article

References (80)

1. Jang, M.S. et al. 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218–220.
2. Surh, Y.J. et al. 2001. Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat. Res. 480: 243–268.
3. Hao, H.D. & L.R. He. 2004. Mechanisms of cardiovascular protection by resveratrol. J. Med. Food 7: 290–298.
4. Li, H.G., N. Xia & U. Förstermann. 2012. Cardiovascular effects and molecular targets of resveratrol. Nitric Oxide 26: 102–110.
5. de la Lastra, C.A. & I. Villegas. 2005. Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol. Nutr. Food Res. 49: 405–430.
6. Harikumar, K.B. & B.B. Aggarwal. 2008. Resveratrol—a multitargeted agent for age-associated chronic diseases. Cell Cycle 7: 1020–1035.
7. Xu, Q. & L.Y. Si. 2012. Resveratrol role in cardiovascular and metabolic health and potential mechanisms of action. Nutr. Res. 32: 648–658.
8. Park, S.J. et al. 2012. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148: 421–433.
9. Shen, C.L. et al. 2012. Fruits and dietary phytochemicals in bone protection. Nutr. Res. 32: 897–910.
10. Richer, S. et al. 2013. Observation of human retinal remodeling in octogenarians with a resveratrol based nutritional supplement. Nutrients 5: 1989–2005.
11. Wood, J.G. et al. 2004. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430: 686–689.
12. Baur, J.A. 2010. Resveratrol, sirtuins, and the promise of a DR mimetic. Mech. Ageing Dev. 131: 261–269.
13. Riviere, C. et al. 2007. Inhibitory activity of stilbenes on Alzheimer's beta-amyloid fibrils in vitro. Bioorg. Med. Chem. 15: 1160–1167.
14. Sun, A.Y. et al. 2010. Resveratrol as a therapeutic agent for neurodegenerative diseases. Mol. Neurobiol. 41: 375–383.
15. Kundu, J.K. & Y.J. Surh. 2008. Cancer chemopreventive and therapeutic potential of resveratrol: Mechanistic perspectives. Cancer Lett. 269: 243–261.
16. Tennen, R.I., E. Michishita-Kioi & K.F. Chua. 2012. Finding a target for resveratrol. Cell 148: 387–389.
17. Shankar, S., G. Singh & R.K. Srivastava. 2007. Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front. Biosci. 12: 4839–4854.
18. Aguirre, L. et al. 2014. Resveratrol: anti-obesity mechanisms of action. Molecules 19: 18632–18655.
19. Shukla, Y. & R. Singh. 2011. “Resveratrol and cellular mechanisms of cancer prevention.” In Resveratrol and Health. Vol. 1215: O. Vang & D.K. Das, Eds.: 1–8. Malden: Wiley-Blackwell.
20. Widlund, A.L., J.A. Baur & O. Vang. 2013. mTOR: more targets of resveratrol? Expert Rev. Mol. Med. 15: 15.
21. Phuah, N.H. & N.H. Nagoor. 2014. Regulation of microRNAs by natural agents: new strategies in cancer therapies. BioMed Res. Int. 2014: 804510.
22. Lancon, A. et al. 2012. Control of MicroRNA expression as a new way for resveratrol to deliver its beneficial effects. J. Agric. Food Chem. 60: 8783–8789.
23. Hwang, J.T., D.Y. Kwon & S.H. Yoon. 2009. AMP-activated protein kinase: a potential target for the diseases prevention by natural occurring polyphenols. New Biotech. 26: 17–22.
24. Kundu, J.K. & Y.J. Surh. 2004. Molecular basis of chemoprevention by resveratrol: NF-kappa B and AP-1 as potential targets. Mutat. Res. 555: 65–80.
25. Venturelli, S. et al. 2013. Resveratrol as a Pan-HDAC inhibitor alters the acetylation status of jistone proteins in human-derived hepatoblastoma cells. PLoS One 8: 12.
26. Gusman, J., H. Malonne & G. Atassi. 2001. A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 22: 1111–1117.
27. Miura, T., S. Muraoka & Y. Fujimoto. 2002. Inactivation of creatine kinase induced by stilbene derivatives. Pharmacol. Toxicol. 90: 66–72.
28. Murias, M. et al. 2004. Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg. Med. Chem. 12: 5571–5578.
29. Zykova, T.A. et al. 2008. Resveratrol directly targets COX-2 to inhibit carcinogenesis. Mol. Carcinog. 47: 797–805.
30. Xu, L.H. et al. 2014. COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models. Sci. Transl. Med. 6: 12.
31. Chan, A.T. et al. 2012. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev. Res. 5: 164–178.
32. Ghosh, N. et al. 2010. COX-2 as a target for cancer chemotherapy. Pharmacol. Rep. 62: 233–244.
33. Calamini, B. et al. 2010. Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem. J. 429: 273–282.
34. Peters-Golden, M. & W.R. Henderson. 2007. Mechanisms of disease: Leukotrienes. N. Engl. J. Med. 357: 1841–1854.
35. Oi, N. et al. 2010. Resveratrol, a red wine polyphenol, suppresses pancreatic cancer by inhibiting leukotriene A(4) hydrolase. Cancer Res. 70: 9755–9764.
36. Snelgrove, R.J. et al. 2010. A critical role for LTA(4)H in limiting chronic pulmonary neutrophilic inflammation. Science 330: 90–94.
37. Zhao, Y., E.B. Butler & M. Tan. 2013. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 4: 10.
38. Flavin, R. et al. 2010. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 6: 551–562.
39. Kuhajda, F.P. 2006. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res. 66: 5977–5980.
40. Li, B.H. et al. 2005. Structure-activity relationship of polyphenols that inhibit fatty acid synthase. J. Biochem. 138: 679–685.
41. Pandey, P.R. et al. 2011. Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase. Breast Cancer Res. Treat. 130: 387–398.
42. Patel, K.R. et al. 2013. Sulfate metabolites provide an intracellular pool for resveratrol generation and induce autophagy with senescence. Sci. Transl. Med. 5: 12.
43. Ito, Y. et al. 2013. Identification of carbonyl reductase 1 as a resveratrol-binding protein by affinity chromatography using 4′–Amino-3,5-dihydroxy-trans-stilbene. J. Nutr. Sci. Vitaminol. 59: 358–364.
44. Wang, Z.R. et al. 2004. Identification and purification of resveratrol targeting proteins using immobilized resveratrol affinity chromatography. Biochem. Biophys. Res. Commun. 323: 743–749.
45. Buryanovskyy, L. et al. 2004. Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry 43: 11417–11426.
46. Wang, W., W-D. Le, T. Pan, et al. 2008. Association of NRH: quinone oxidoreductase 2 gene promoter polymorphism with higher gene expression and increased susceptibility to Parkinson's disease. J. Gerontol. A Biol. Sci. Med. Sci. 63: 127–134.
47. Neves, M.A.C. et al. 2007. Combining computational and biochemical studies for a rationale on the anti-aromatase activity of natural polyphenols. ChemMedChem. 2: 1750–1762.
48. Hsieh, T.C. et al. 2008. Identification of glutathione sulfotransferase-pi (GSTP1) as a new resveratrol targeting protein (RTP) and studies of resveratrol-responsive protein changes by resveratrol affinity chromatography. Anticancer Res. 28: 29–36.
49. Roman, J. 2008. Peroxisome proliferator-activated receptor gamma and lung cancer biology. J. Invest. Med. 56: 528–533.
50. Baur, J.A. et al. 2006. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444: 337–342.
51. Calleri, E. et al. 2014. Resveratrol and its metabolites bind to PPARs. ChemBioChem. 15: 1154–1160.
52. Heckman, P.R.A., C. Wouters & J. Prickaerts. 2015. Phosphodiesterase inhibitors as a target for cognition enhancement in aging and Alzheimer's disease: a translational overview. Curr. Pharm. Design 21: 317–331.
53. Movsesian, M. et al. 2009. Phosphodiesterase inhibition in heart failure. Heart Fail. Rev. 14: 255–263.
54. Tashkin, D.P. 2014. Roflumilast: the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD. Expert Opin. Pharmacother. 15: 85–96.
55. Athar, M. et al. 2009. Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch. Biochem. Biophys. 486: 95–102.
56. Jo, J.Y., E.G. De Mejia & M.A. Lila. 2006. Catalytic inhibition of human DNA topoisomerase II by interactions of grape cell culture polyphenols. J. Agric. Food Chem. 54: 2083–2087.
57. Dong, Z. 2003. Molecular mechanism of the chemopreventive effect of resveratrol. Mutat. Res. 523: 145–150.
58. Manning, B.D. & L.C. Cantley. 2007. AKT/PKB signaling: Navigating downstream. Cell 129: 1261–1274.
59. Hsieh, T.C. et al. 2014. Biochemical and cellular evidence demonstrating AKT-1 as a binding partner for resveratrol targeting protein NQO2. PLoS One 9: 1.
60. Kumar, C.C. & V. Madison. 2005. AKT crystal structure and AKT-specific inhibitors. Oncogene 24: 7493–7501.
61. Lapenna, S. & A. Giordano. 2009. Cell cycle kinases as therapeutic targets for cancer. Nat. Rev. Drug Discov. 8: 547–566.
62. Lee, J.H. et al. 2014. Direct activation of ATM by resveratrol under oxidizing conditions. PLoS One 9: 10.
63. Stivala, L.A. et al. 2001. Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J. Biol. Chem. 276: 22586–22594.
64. Lange, S.S., K. Takata & R.D. Wood. 2011. DNA polymerases and cancer. Nat. Rev. Cancer 11: 96–110.
65. Slater, S.J. et al. 2003. Inhibition of protein kinase C by resveratrol. Biochim. Biophys. Acta-Mol. Basis Dis. 1637: 59–69.
66. Stewart, J.R., K.L. Christman & C.A. O'Brian. 2000. Effects of resveratrol on the autophosphorylation of phorbol ester-responsive protein kinases—inhibition of protein kinase D but not protein kinase C isozyme autophosphorylation. Biochem. Pharmacol. 60: 1355–1359.
67. Mochly-Rosen, D., K. Das & K.V. Grimes. 2012. Protein kinase C, an elusive therapeutic target? Nat. Rev. Drug Discov. 11: 937–957.
68. Sundram, V., S.C. Chauhan & M. Jaggi. 2011. Emerging roles of protein kinase D1 in cancer. Mol. Cancer Res. 9: 985–996.
69. Haworth, R.S. & M. Avkiran. 2001. Inhibition of protein kinase D by resveratrol. Biochem. Pharmacol. 62: 1647–1651.
70. Sajish, M. & P. Schimmel. 2015. A human tRNA synthetase is a potent PARP1-activating effector target for resveratrol. Nature 519: 370–373.
71. Baell, J. & M.A. Walters. 2014. Chemical con artists foil drug discovery. Nature 513: 481–483.
72. MRC. 2014. Kinase Inhibitor Database. Vol. 2014 http://www.kinase-screen.mrc.ac.uk/screening-compounds/345920. Accessed May 28, 2015.
73. Dokmanovic, M., C. Clarke & P.A. Marks. 2007. Histone deacetylase inhibitors: overview and perspectives. Mol. Cancer Res. 5: 981–989.
74. Baur, J.A. et al. 2012. Are sirtuins viable targets for improving healthspan and lifespan? Nat. Rev. Drug Discov. 11: 443–461.
75. Beher, D. et al. 2009. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem. Biol. Drug Des. 74: 619–624.
76. Borra, M.T., B.C. Smith & J.M. Denu. 2005. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 280: 17187–17195.
77. Liang, Y., W.X. Tian & X.F. Ma. 2013. Inhibitory effects of grape skin extract and resveratrol on fatty acid synthase. BMC Complement Altern. Med. 13: 8.
78. Usha, S., I.M. Johnson & R. Malathi. 2005. Interaction of resveratrol and genistein with nucleic acids. J. Biochem. Mol. Biol. 38: 198–205.
79. Belguendouz, L., L. Fremont & M.T. Gozzelino. 1998. Interaction of transresveratrol with plasma lipoproteins. Biochem. Pharmacol. 55: 811–816.
80. Gledhill, J.R. et al. 2007. Mechanism of inhibition of bovine F-1-ATPase by resveratrol and related polyphenols. Proc. Natl. Acad. Sci. U. S. A. 104: 13632–13637.